Severe SARS-CoV2 Pneumonia
Conditions
Keywords
SARS-CoV2, long term, complication, pneumonia
Brief summary
Studies performed after coronavirus epidemics (severe acute respiratory syndrome coronavirus, SARS-CoV and Middle East respiratory syndrome coronavirus, MERS-CoV) have shown a long-term impact on respiratory morbidity, musculoskeletal and psycho-social repercussions. Patients with SARS-CoV pneumonia had fibrotic pulmonary sequelae at 45 days (lower DLCO in 27.3% of cases and radiological lesions in 21.5% of cases). In the MERS-CoV pneumonia study, patients had radiological sequelae in 33% of cases and the 12-month evaluation showed persistence of radiological abnormalities in 23.7% of the cases despite an improvement in respiratory function. Clinical presentation and therapeutic management of severe SARS-CoV-2 infection are in part similar to those induced by SARS-CoV and MERS-CoV. Long-term respiratory complications are therefore expected.
Detailed description
Objective is to evaluate prevalence of long-term respiratory complications after severe SARS-CoV2 pneumonia.
Interventions
OTHERBlood sample and data record
Blood sample and data record
Sponsors
CHU de Reims
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patient * Patient with with severe SARS-CoV2 pneumonia * Patient consenting to participate to the study * Patient enrolled in the national healthcare insurance program
Exclusion criteria
* Patient under 18 years
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| medium-term respiratory complications | 3 months | Interstitial lung disease diagnosed with a thoracic CT-scan |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| long-term respiratory complications | 12 months | Interstitial lung disease diagnosed with a thoracic CT-scan |
Countries
France
Outcome results
None listed